HELEN KELLER INTERNATIONAL

Lenacapavir: Twice-Yearly Injection Shows High Efficacy in HIV Prevention

6 months ago

• Lenacapavir, administered as a twice-yearly injection, demonstrates a 96% reduction in HIV infection risk compared to background incidence. • Clinical trials reveal lenacapavir's superior efficacy over daily oral PrEP medications like Truvada, particularly addressing adherence challenges. • The FDA is reviewing lenacapavir for potential approval in 2025, offering a promising long-acting option for HIV prevention. • Global health experts emphasize the importance of equitable access and affordability to ensure widespread adoption of lenacapavir.